.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Queensland Health
McKesson
Moodys
Mallinckrodt
Fish and Richardson
Farmers Insurance
Dow
Federal Trade Commission
QuintilesIMS

Generated: December 15, 2017

DrugPatentWatch Database Preview

EPZICOM Drug Profile

« Back to Dashboard

Which patents cover Epzicom, and when can generic versions of Epzicom launch?

Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty patent family members in fifty-seven countries and fifteen supplementary protection certificates in ten countries.

The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EPZICOM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for EPZICOM

Drugname Dosage Strength RLD Submissiondate
abacavir sulfate and lamivudineTablets600 mg/300 mgEpzicom9/27/2007

International Patent Family for Tradename: EPZICOM

Country Document Number Estimated Expiration
New Zealand500865► Subscribe
African Intellectual Property Organization (OAPI)11304► Subscribe
China1263529► Subscribe
Denmark0983271► Subscribe
Denmark0517145► Subscribe
Peru78799► Subscribe
Norway974510► Subscribe
Malaysia120151► Subscribe
African Regional IP Organization (ARIPO)300► Subscribe
Slovenia817637► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EPZICOM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0817637/01Switzerland► SubscribePRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005
C0022France► SubscribePRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
8Finland► Subscribe
0195Netherlands► Subscribe300195, 20160328, EXPIRES: 20191216
171Luxembourg► Subscribe91171, EXPIRES: 20191217
2005 00028Denmark► Subscribe
/2005Austria► SubscribePRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
C/GB05/027United Kingdom► SubscribeSPC/GB05/027: 20050922, EXPIRES: 20191216
90028Netherlands► SubscribePRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708
99C0033Belgium► SubscribePRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Dow
Citi
Colorcon
QuintilesIMS
Express Scripts
Argus Health
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot